Ariti is pleased to announce its accession to the Your Pharma Partner in Europe (YPP) network, further strengthening its strategic presence in the European pharmaceutical sector and expanding its opportunities for developing new partnerships. Your Pharma Partner in Europe is an alliance of independent pharmaceutical companies established to support pharmaceutical…
LONDON – February [2], 2026 – Ayrmid, Ltd. (“Ayrmid” or the “Company”), the parent company of Gamida Cell Inc., today announced that it has entered into an exclusive distribution agreement with Ariti S.A., a Greece based pharmaceutical company for the distribution of Omisirge (Omidubicel-onlv) in Greece and Cyprus. Under the terms of…
Ariti S.A of Athens, Greece, announced today a strategic partnership with Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases. Through this collaboration, Ariti will spearhead multiple initiatives aiming to raise awareness of rare melanocortin-4 receptor (MC4R) pathway…
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced its first named patient sales of its flagship drug Pepaxti in Greece. The sales were made possible through Oncopeptides’ partnership with Ariti S.A., a company specialized on medical and pharmaceutical supply in Greece. Since receiving the…